Rieck Susanne, Rundfeldt Chris, Tipold Andrea
Department of Small Animal Medicine and Surgery, University of Veterinary Medicine, and Center for Systems Neuroscience, Hannover, Germany.
Vet J. 2006 Jul;172(1):86-95. doi: 10.1016/j.tvjl.2005.04.003.
A new antiepileptic and anxiolytic drug, ELB138, was evaluated in a clinical pilot study in dogs with newly diagnosed or chronic idiopathic epilepsy. The purpose was to verify clinically the anticonvulsant effectiveness of this substance, which had already been demonstrated experimentally. Data from 29 dogs treated with ELB138 were compared with results obtained retrospectively from 82 dogs treated with conventional antiepileptic medication. The reduction in seizure frequency using ELB138 in dogs with newly diagnosed idiopathic epilepsy was comparable to the reduction in dogs treated either with phenobarbital or primidone. In dogs with chronic epilepsy and add-on therapy with either ELB138 or potassium bromide, such supplementation reduced the seizure frequency and the duration and severity of seizures. The most obvious difference between ELB138 treatment and conventional medications became clear in the evaluation of side effects, which in those dogs treated with ELB138 were rare, and consisted mostly of transient polyphagia. This pilot study confirmed that ELB138 has a potent anticonvulsant effect in dogs with idiopathic epilepsy. These results will form the basis for a multicentre, blinded study.
一种新型抗癫痫和抗焦虑药物ELB138，在一项针对新诊断或慢性特发性癫痫犬的临床初步研究中进行了评估。目的是在临床上验证这种已在实验中得到证实的物质的抗惊厥效果。将29只接受ELB138治疗的犬的数据与回顾性收集的82只接受传统抗癫痫药物治疗的犬的结果进行比较。在新诊断的特发性癫痫犬中，使用ELB138降低癫痫发作频率的效果与使用苯巴比妥或扑米酮治疗的犬相当。在慢性癫痫犬中，添加ELB138或溴化钾进行辅助治疗，可降低癫痫发作频率、发作持续时间和严重程度。ELB138治疗与传统药物之间最明显的差异在副作用评估中显现出来，接受ELB138治疗的犬副作用很少，主要是短暂的多食症。这项初步研究证实，ELB138对特发性癫痫犬具有强大的抗惊厥作用。这些结果将为一项多中心、双盲研究奠定基础。
